Recruiting studies: Advanced Lung Non Squamous Non Small Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331 A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination Wi
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07459751 Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655 Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer Wit
Phase 3 · 37 location(s) · Allist Pharmaceuticals, Inc. · NCT06416410 A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With
EARLY_Phase 1 · 1 location(s) · People's Hospital of Quzhou · NCT07647094 First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186 This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497 Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in P
Phase 2 · 8 location(s) · CrystalGenomics, Inc. · NCT05841472 Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Phase 2 · 1 location(s) · Brown University · NCT06974604 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · 260 location(s) · Hoffmann-La Roche · NCT06793215 A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470 A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06422403 Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305 Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814 A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participan
Phase 3 · 351 location(s) · Mirati Therapeutics Inc. · NCT06875310 A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet
Phase 2 · 71 location(s) · Bristol-Myers Squibb · NCT07680764 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC H
Phase 2 · 1 location(s) · Avistone Biotechnology Co., Ltd. · NCT07336732 Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Tasca Therapeutics · NCT07030257 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Met
Phase 1/Phase 2 · 3 location(s) · GI Innovation, Inc. · NCT07172802 A Retrospective Real-World Study Based on RATIONALE-307
Phase N/A · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07478809 A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/Phase 2 · 20 location(s) · Hummingbird Bioscience · NCT05910827 A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/Phase 2 · 4 location(s) · Cancer Research UK · NCT06380816 A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06735391 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793 First in Human Study of SIM0610 in Solid Tumors
Phase 1 · 7 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT07348211 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malign
Phase 1/Phase 2 · 13 location(s) · GV20 Therapeutics · NCT05669430 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · 312 location(s) · AstraZeneca · NCT06692738 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Phase 1/Phase 2 · 6 location(s) · Simcha IL-18, Inc. · NCT04787042

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.